Sophiris Bio, Inc. (SPHS) financial statements (2021 and earlier)

Company profile

Business Address 1258 PROSPECT STREET
LA JOLLA, CA 92037
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:13262982348
Cash and cash equivalents1116136415
Short-term investments2101631933
Other undisclosed cash, cash equivalents, and short-term investments   00 
Receivables 0000 
Prepaid expense011034
Other undisclosed current assets0  (0)(0)0
Total current assets:13273092652
Noncurrent Assets
Property, plant and equipment000000
Other noncurrent assets 00000
Total noncurrent assets:000000
TOTAL ASSETS:13273092652
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities322165
Accounts payable210131
Accrued liabilities112122
Employee-related liabilities    11
Interest and dividends payable    0 
Debt20 217
Other undisclosed current liabilities    (1)(1)
Total current liabilities:5323611
Noncurrent Liabilities
Long-term debt and lease obligation56 45 
Long-term debt, excluding current maturities56 45 
Liabilities, other than long-term debt11013001
Deferred compensation liability, classified  000 
Derivative instruments and hedges, liabilities11013  1
Other undisclosed noncurrent liabilities     0
Total noncurrent liabilities:61713451
Total liabilities:11191671112
Stockholders' equity
Stockholders' equity attributable to parent, including:281421540
Common stock131131131114113111
Additional paid in capital272624181714
Accumulated other comprehensive income000000
Accumulated deficit(156)(150)(141)(130)(116) 
Other undisclosed stockholders' equity attributable to parent     (85)
Total stockholders' equity:281421540
TOTAL LIABILITIES AND EQUITY:13273092652

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues000005
Revenue, net    5
Net investment income00000 
Cost of revenue
(Cost of Goods and Services Sold)
   (1)(1)(1)
Gross profit:000(1)(1)4
Operating expenses(15)(12)(10)(13)(30)(15)
Operating loss:(15)(12)(10)(14)(31)(10)
Nonoperating income (expense)83(1)(1)(1)(1)
Foreign currency transaction loss, before tax    (0)(0)
Other nonoperating income (expense)0(0)(0)(0)(0)(0)
Interest and debt expense(1)(0)0(1)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(7)(9)(11)(15)(32)(13)
Other undisclosed income (loss) from continuing operations before income taxes0(0)(0)112
Loss from continuing operations before income taxes:(7)(9)(11)(14)(31)(11)
Income tax expense     (1)
Net loss available to common stockholders, diluted:(7)(9)(11)(14)(31)(11)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(7)(9)(11)(14)(31)(11)
Comprehensive loss:(7)(9)(11)(14)(31)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)  00
Comprehensive loss, net of tax, attributable to parent:(7)(9)(11)(14)(31)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: